Brenda Dooley founded AXIS Consulting in early 2012. As an experienced market access strategist with 20+ years of international biopharma industry experience, Brenda and her team have developed over 100 bespoke and high-quality reimbursement submissions for the Irish authorities. As Chief Executive at AXIS, Brenda has led the company to its position as the dominant provider for submissions to the Irish authorities and is now leading the expansion of the company into the UK providing HTA submissions to NICE/SMC/AWMSG.
The purpose of AXIS Consulting is to provide unhindered access for patients to effective health interventions, achieved through agile and nimble strategic engagement with the national-level reimbursement process. It is the vision of AXIS to be the partner of choice for a selected & aligned customer base – delivering expertly customised UK & Ireland reimbursement submissions.